AFFX Affymetrix, Inc.

Clinical Data Inc. (NASDAQ:CLDA) and Affymetrix Inc. (NASDAQ:AFFX) today announced a marketing agreement for a new drug metabolism service using the Affymetrix Drug Metabolizing Enzymes and Transporter (DMET) Early Access solution. Cogenics and Epidauros Biotechnologie AG, both subsidiaries of Clinical Data Inc., will offer the DMET services on a global basis, with limited exclusivity in Europe. Affymetrix (DMET) Early Access solution is currently the world�s most comprehensive method for assaying the genetics of drug metabolism. The service will enable pharmaceutical customers to generate comprehensive genetic profiles of a patient�s metabolic status to gain a better understanding of pharmacokinetic drug response. In a separate release issued today, Affymetrix announced the availability of its DMET Early Access Solution. Affymetrix has been working closely with Cogenics to develop the DMET technology, which directly assays 1,069 total biomarkers in 160 Absorption, Distribution, Metabolism and Excretion (ADME) genes. The kit includes cytochrome p450 enzymes and drug transporters like MDR1, genetic biomarkers with which Cogenics and Epidauros have extensive working experience. �The Affymetrix DMET Early Access solution is the only product with comprehensive coverage of all ADME drug metabolism biomarkers to date. As the first certified DMET commercial provider, we have analyzed thousands of DMET samples over the last few years and we are confident that our Early Access service offering will yield valuable, high-quality data to our pharmaceutical partners on a global basis,� said Michael Lutz, Global General Manager of Cogenics and Chief Executive Officer of Epidauros. �We believe that Cogenics� and Epidauros� expertise in genetic biomarker discovery and history with ADME studies will greatly enhance the DMET offering by making it more attractive, comprehensive and valuable to pharmaceutical customers seeking to address drug metabolism issues that arise in drug development,� said Pratima Rao, Senior Director of Product Marketing at Affymetrix. For more information on Cogenics� and Epidauros� DMET solutions, please call 1-877-226-4364 (U.S.) or +49 8158 9985 0 (E.U.), or email sales@cogenics.com or contact@epidauros.com. About Clinical Data Inc. Clinical Data, Inc. is unlocking the potential of molecular discovery, From Targeted Science to Better Healthcare�. Its PGxHealth� division focuses on proprietary biomarker and pharmacogenetic test development as well as targeted therapeutics to help predict drug safety and efficacy, thereby reducing health care costs and improving clinical outcomes. Its Cogenics� division provides a broad range of molecular and pharmacogenomics services to pharmaceutical, biotechnology, and academic organizations in both research and regulated environments. Through these divisions, Clinical Data is leveraging advances in pharmacogenomics to provide tangible benefits for patients, doctors, scientists and health plans worldwide. Visit the company's website at www.clda.com for more information. About Cogenics and Epidauros Cogenics, a subsidiary of Clinical Data, offers more than 18 years of experience as a trusted provider of the broadest range of pharmacogenomics and molecular biology services available globally. Cogenics provides integrated services for nucleic acid extraction, genotyping, sequencing, QPCR, and gene expression, as well as serving as a biorepository, for both research and regulated environments: GLP, cGMP and CLIA. Cogenics combines operations from the acquisitions of Genaissance Pharmaceuticals, Lark Technologies (US & UK), Icoria, Genome Express (France) and Epidauros (Germany). Its customers include some of the world�s most respected pharmaceutical and biotechnology companies, agencies of the US National Institutes of Health, leading government and academic researchers in the international life science community, and major agricultural companies and agencies. For more information, please visit www.cogenics.com. Epidauros was acquired by Clinical Data in 2007. Before the acquisition, the company has established itself as a worldwide leading Pharmacogenetic Research Organization (PRO) providing innovative, integrated and value-added solutions to an international customer base consisting of pharmaceutical companies, CROs and other companies acting in the field of health care. Since its foundation in 1997, Epidauros has brought together a network of competent partners to do pharmacogenetic-related research and has established its own intellectual property base in the field of drug transporters, e.g. MDR1 and cytochrome P450 enzymes. The company is located in Bernried near Munich. For more information, please visit www.epidauros.com. About Affymetrix Affymetrix GeneChip� microarray technology is the industry-standard tool for analyzing complex genetic information. After inventing microarray technology in the late 1980s, Affymetrix scientists have been dedicated to developing innovative products that provide researchers with a more complete view of the genome. These products continue to accelerate genetic research and enable scientists to develop diagnostics and tailor treatments for individual patients by identifying and measuring the genetic information associated with complex diseases. Today, Affymetrix technology is used by the world�s top pharmaceutical, diagnostic and biotechnology companies, as well as leading academic, government and not-for-profit research institutes. More than 1,600 systems have been shipped around the world and more than 10,500 peer-reviewed papers have been published using the technology. Affymetrix is headquartered in Santa Clara, Calif., and has manufacturing facilities in Sacramento, Calif., and Singapore. The company has about 1,100 employees worldwide and maintains sales and distribution operations across Europe and Asia. For more information about Affymetrix, please visit: www.affymetrix.com. SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 Forward-looking Statements of Clinical Data, Inc. This press release contains certain forward-looking information about Clinical Data that is intended to be covered by the safe harbor for �forward-looking statements� provided by the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. Words such as �expect(s),� �feel(s),� �believe(s),� �will,� �may,� �anticipate(s)� and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to statements regarding: our ability to successfully integrate the operations, business, technology and intellectual property obtained in our acquisitions; our ability to obtain regulatory approval for, and successfully introduce our new products; our ability to expand our long-term business opportunities; our ability to maintain normal terms with our customers and partners; financial projections and estimates and their underlying assumptions; and statements regarding future performance. All of such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of the Company, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include, but are not limited to: whether and to what extent the DMET offering will be accepted by the market; the extent to which genetic markers (haplotypes) are predictive of clinical outcomes and drug efficacy and safety; our ability to achieve the expected synergies and operating efficiencies from all of our acquisitions; the strength of our intellectual property rights; competition from pharmaceutical, biotechnology and diagnostics companies; the development of and our ability to take advantage of the market for pharmacogenetic and biomarker products and services; general economic downturns; and other risks contained in our various SEC reports and filings, including but not limited to our Annual Report on Form�10-K for the fiscal year ended March 31, 2007, our Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2007, and our Current Reports on Form 8-K filed with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof, and we do not undertake any obligation to revise and disseminate forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of or non-occurrence of any events. Forward-looking Statements of Affymetrix, Inc. All statements in this press release that are not historical are �forward-looking statements� within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix� �expectations,� �beliefs,� �hopes,� �intentions,� �strategies� or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected, including, but not limited to: risks and uncertainties relating to commercial success of the marketing agreement between Affymetrix, Clinical Data, Cogenics and Epidauros Biotechnologie AG discussed in this press release; risks of the company�s ability to achieve and sustain higher levels of revenue, higher gross margins and reduced operating expenses; uncertainties related to technological approaches, manufacturing and product development; personnel retention; uncertainties related to cost and pricing of Affymetrix products; dependence on collaborative partners; uncertainties related to sole-source suppliers; risks associated with acquisitions; uncertainties relating to FDA and other regulatory approvals; competition; risks relating to intellectual property of others and the uncertainties of patent protection and litigation. These and other risk factors are discussed in Affymetrix� Form 10-K for the year ended December 31, 2006, and other SEC reports, including its Quarterly Reports on Form 10-Q for subsequent quarterly periods. Affymetrix expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Affymetrix� expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.